Direct-to-CNS CAR T cells for PCNSL treatment
Official title: Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
Funded at Beckman Research Institute/city of Hope · NIH-11399143 · Data updated 2026-11-12
A patient-focused look at using CD19 CAR T cells delivered directly into the brain to treat primary CNS lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 9, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $710,482 |
| NIH project number | 5R01CA266611-05 |
| Project ID | NIH-11399143 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with primary central nervous system lymphoma who may be eligible for CNS-directed CAR T-cell therapy.
✕Less likely to help
Patients with contraindications to CAR T-cell therapy or with disease characteristics unlikely to respond to CNS-delivered CAR T cells.
What this research studies
This project tests a CAR T-cell therapy delivered straight into the brain to target cancer in the CNS, aiming to overcome barriers that limit traditional IV therapy. It builds on prior lab and early human work showing CAR T cells can reach the CNS and fight tumor cells. By refining a brain-delivery approach, researchers hope for better tumor control and durability of response for people with PCNSL. The study is conducted at City of Hope with established manufacturing and safety checks to oversee treatment delivery. If successful, this could open new options for patients with this challenging disease.
Why it matters
Potential benefit: If successful, patients could experience better tumor control and potentially longer survival with a therapy tailored to reach tumors inside the CNS.
How similar studies have gone: Earlier IV CAR T-cell trials show CNS activity, and locoregional delivery in other CNS cancers has shown promise in early studies.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wang, Xiuli — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Xiuli
Related research
Other NIH-funded projects on the same topics.
-
CD19 CAR T cells given into the brain fluid for primary CNS lymphoma
This work uses CD19-directed CAR T cells delivered into the fluid around the brain to treat people with primary central nervous system lymphoma.
-
Using targeted immune cells to treat brain lymphoma
This study is testing a new way to treat primary central nervous system lymphoma by delivering special immune cells directly into the brain to help them better fight the cancer, and it's designed for patients looking for more effective options than what's currently available.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.